Clinical Observation Of The Regimen For Docetaxel Combined With Cisplatin And Dedaplain Chemotherapy In The Treatment With Non-small Cell Lung Cancer

Objective: To summarize and observe zhe clinical results and toxicity of Gefitinib in zhe treatment of zhe patients with advanced non-samll cell lung cancer (NSCLC) who failed prior chemotherapy. Methods: Thirty-five patients with unresectable IIIb or IV NSCLC who admitted to theXin jiang Tumor Hospital from JUNE 2004 to AUGEST 2006, Gefitinib was oralled administered 250 mg once daily until disease progression or the occurrence of intolerable toxicity. Results: Among the 35 NSCLC, no complete response(CR) and 19 patrial response(PR),The objective response rate (CR+PR) was 54.29%, stability disease rate was 25.71% and Disease control rate (CR+PR+SD)was 80%, The most effective symtoms was cough and pain. The median overall survival time was 32.months.22/35(62.86%) patient was even alive to zhe eunderlying time. The effect of gefitinib was related to sexual and smoking. The effect of zhe female is better than male, non-somking is better than smoking. The most common drug-related adverse events were grade I or II skin rash (22.86%,8.57%) and diarrhea (17.14%) with no need of further treatment. Conclusions: Gefitinib is effective, safe and easy in treating patients evenfemale, non-somking and adenocarcinoma with locally advanced or metastatic NCSLC after failure of previous chemotherapy. It is tolerated by the patients and may remarkablely impove their symptoms and quality of life.